title: Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study.
abstract: From May 1988 to March 1990, 17 consecutive patients with histologically proven malignant mesothelioma were treated with epirubicin 75 mg/sqm i.v. on day 1 and ifosfamide 1.8 gr/sqm/day i.v. from day 1-5. Treatment was repeated every 3 weeks until progression. Fifty-three chemotherapy cycles were administered to the 17 patients treated (median, 3 cycles/patient). No complete responses, 1 partial response, 8 stable diseases and 8 progressions were noted. Toxocity was acceptable and no treatment-related deaths occurred. Actuarial median survival was 6 months. In this study, a combination of full doses of epirubicin and ifosfamide did not prove to be active in malignant mesothelioma.
authors.affiliation: Division of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
authors.forename: M D
authors.initials: MD
authors.lastname: Magri
authors.forename: S
authors.initials: S
authors.lastname: Foladore
authors.forename: A
authors.initials: A
authors.lastname: Veronesi
authors.forename: C
authors.initials: C
authors.lastname: Serra
authors.forename: M
authors.initials: M
authors.lastname: Nicotra
authors.forename: M
authors.initials: M
authors.lastname: Tommasi
authors.forename: G
authors.initials: G
authors.lastname: Grandi
authors.forename: S
authors.initials: S
authors.lastname: Monfardini
authors.forename: C
authors.initials: C
authors.lastname: Bianchi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged
chemical_list: D015251:Epirubicin; D007069:Ifosfamide